| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10013568 | HBV | ENSG00000151617.17 | protein_coding | EDNRA | No | No | 1909 | P25101 |
| TVIS20026127 | HPV | ENSG00000151617.17 | protein_coding | EDNRA | No | No | 1909 | P25101 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | EDNRA |
|---|---|
| DrugBank ID | DB08932 |
| Drug Name | Macitentan |
| Target ID | BE0000521 |
| UniProt ID | P25101 |
| Regulation Type | antagonist |
| PubMed IDs | 22862294; 29719121; 29540357 |
| Citations | Bolli MH, Boss C, Binkert C, Buchmann S, Bur D, Hess P, Iglarz M, Meyer S, Rein J, Rey M, Treiber A, Clozel M, Fischli W, Weller T: The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-p ropylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem. 2012 Sep 13;55(17):7849-61. doi: 10.1021/jm3009103. Epub 2012 Aug 16.@@Bedan M, Grimm D, Wehland M, Simonsen U, Infanger M, Kruger M: A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension. Basic Clin Pharmacol Toxicol. 2018 Aug;123(2):103-113. doi: 10.1111/bcpt.13033. Epub 2018 Jun 5.@@Thenappan T, Ormiston ML, Ryan JJ, Archer SL: Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018 Mar 14;360:j5492. doi: 10.1136/bmj.j5492. |
| Groups | Approved |
| Direct Classification | Halopyrimidines |
| SMILES | CCCNS(=O)(=O)NC1=C(C(OCCOC2=NC=C(Br)C=N2)=NC=N1)C1=CC=C(Br)C=C1 |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL2103873 |
